Prevention of Delayed Graft Function Using Eculizumab Therapy (PROTECT Study)

NCT02145182 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

288

Enrollment

INDUSTRY

Sponsor class

Conditions

Delayed Graft Function

Interventions

DRUG: Eculizumab
DRUG: Placebo

Sponsor

Alexion Pharmaceuticals, Inc.

Collaborators

[object Object]